HILLSIDE, N.J. -- Integrated BioPharma, Inc. today announced that INB:Biotechnologies Inc. (formerly NuCycle Therapy Inc.), INB's wholly owned biotech subsidiary, has entered into an agreement with Fraunhofer USA, to develop a flu vaccine using transient expression vectors based on plant viruses. This technique involves living plants as the production system for the vaccine. INB Biotechnologies will be using the same technology for the flu vaccine that is being developed for the oral anthrax vaccine in its previously announced Cooperative Research and Development Agreement signed with the United States Navy last month.
"This agreement enables the company to build on its platform of vaccine-related technologies to radically improve the manner in which vaccines are manufactured and delivered," said Integrated BioPharma chairman and CEO E. Gerald Kay.
INB Biotechnologies' plant technology may offer vaccines that are produced more quickly, less expensively and with higher purity then current production methods. A faster development time is especially important if there is a need to adapt a vaccine due to the presence of a new flu strain.
Source: Integrated BioPharma, Inc
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.